外媒：中国COVID-19 PCR测试将于2022年达到峰值

▲全球视野 本土思考

在病例减少到季节性周期之前，大规模检测将推动市场增长。

GlobalData显示，随着病例进入类似于流感的季节性感染周期，中国2019冠状病毒聚合酶链反应(PCR)检测的市场价值预计将在2022年达到20亿美元的峰值，然后检测需求开始减少。

预计该市场将受到该国旅行的大规模测试策略和PCR测试要求的推动。GlobalData的医疗设备分析师Bhaskar Vittal表示，COVID-19测试市场预计将在未来两年内增长。

预计该市场将受到该国大规模检测战略和旅行PCR检测要求的推动。GlobalData的医疗设备分析师Bhaskar Vittal评论称，COVID-19检测市场预计将在未来两年增长。

Vittal说”“中国在控制新冠肺炎疫情蔓延方面做了大量工作。然而，由于疫情仍然是一个全球性问题，中国重新开放边境使其很容易再次受到COVID-19传播的影响，可能需要大规模的核酸筛查计划，以评估风险和应对感染”。

此外，由于对快速检测解决方案的需求不断增长，以扩大进行检测的数量，医护点核酸扩增检测(NAATs)受到越来越多的关注。Vittal补充说:“由于医生和患者的偏好，多重复合NAATs有望得到应用。”＊

China's COVID-19 PCR tests to peak in 2022

Mass testing will be driving growth in the market before cases recede to a seasonal cycle.

The COVID-19 polymerase chain reaction (PCR) tests market in China is projected to hit a peak market value of $2b in 2022 before demand for tests starts to recede as cases are expected to move to a seasonal infection cycle similar to the flu, according to GlobalData.

The market is expected to be driven by the country’s mass testing strategy and PCR testing requirements for travelling. GlobalData’s medical devices analyst Bhaskar Vittal commented that the market for COVID-19 tests are expected to grow over the next two years.

“China has done a tremendous job in controlling the spread of COVID-19. However, with the pandemic still very much a global issue, the re-opening of China’s borders makes it vulnerable to the spread of COVID-19 again and might need a mass nucleic acid screening program to assess the risk and tackle the infection,” Vittal said.

Furthermore, point-of-care Nucleic Acid Amplification Tests (NAATs) are gaining traction due to rising demand for rapid test solutions to expand the number of tests performed. “Multiplex NAATs are expected to gain usage due to physician and patient preference,” Vittal added.